Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
BMC Nephrol ; 24(1): 93, 2023 04 10.
Article in English | MEDLINE | ID: mdl-37038101

ABSTRACT

BACKGROUND: Patients with chronic kidney disease frequently develop neurological complications including confusion and altered consciousness. Non-convulsive status epilepticus, which is characterized by a change in behavior and/or mental process accompanied by epileptiform discharges on electroencephalogram in the absence of convulsive seizures, is one of the overlooked causes of altered consciousness. The incidence and precise pathophysiological mechanism of non-convulsive status epilepticus in patients with kidney disease, and especially in patients with electrolyte disturbances, remains unknown. We recently treated an older patient with chronic kidney disease and severe hyperkalemia in whom non-convulsive status epilepticus developed following a correction of severe hyperkalemia. CASE PRESENTATION: An 82-year-old male was admitted to our hospital at midnight because of weakness of all four limbs (Day 1). He underwent urgent hemodialysis for severe hyperkalemia (9.84 mEq/L) and his serum potassium concentration decreased to 4.97 mEq/L. He regained full consciousness and his limb weakness improved on the morning of Day 2, but he became confused in the evening. Electroencephalogram revealed repeated low-voltage ictal discharges in the right occipital region and a diagnosis of non-convulsive status epilepticus was made. Following medication with fosphenytoin and phenytoin, the patient became fully alert and orientated on Day 8. CONCLUSION: We speculate that a rapid correction of hyperkalemia was the possible cause of non-convulsive status epilepticus development. To our knowledge, this is the first report of non-convulsive status epilepticus from a potassium abnormality. We described a case of this condition in detail and summarized 78 previous case reports of non-convulsive status epilepticus with kidney disease or electrolyte disturbances.


Subject(s)
Hyperkalemia , Status Epilepticus , Male , Humans , Aged, 80 and over , Hyperkalemia/etiology , Hyperkalemia/therapy , Status Epilepticus/drug therapy , Status Epilepticus/diagnosis , Seizures , Confusion/etiology , Potassium/therapeutic use , Electrolytes
2.
Kidney Blood Press Res ; 46(2): 173-184, 2021.
Article in English | MEDLINE | ID: mdl-33677450

ABSTRACT

INTRODUCTION: Angiotensin receptor blockers (ARBs) are preferably used in hypertensive patients with CKD. Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood. We compared the antiproteinuric effect of azilsartan and candesartan in CKD patients in an open-label, randomized, crossover trial. METHODS: A total of 111 patients were treated with 20 mg of azilsartan daily for 2 months as a run-in period. After the run-in period, patients were randomized into 2 arms and received either 20 mg of azilsartan or 8 mg of candesartan daily for 3 months in a crossover trial. The primary outcome was the percent change in urinary protein-to-Cr ratio (UPCR). RESULTS: Ninety-five patients completed the trial. The mean age was 64.3 years. The estimated glomerular filtration rate (eGFR) and UPCR were 41.5 mL/min/1.73 m2 and 1.8 g/gCr, respectively. The baseline systolic and diastolic blood pressures were 131.4 and 71.0 mm Hg, respectively. The mean percent change in the UPCR was -3.8% in the azilsartan group and 30.8% in the candesartan group at the 1st endpoint (p = 0.0004), and 6.1% in the azilsartan group and 25.8% in the candesartan group at the 2nd (final) endpoint (p = 0.029). The incidence of adverse events, including eGFR levels and serum potassium levels, was not significantly different between the groups. CONCLUSION: A 20 mg azilsartan dose had potent antiproteinuric effects compared with an 8 mg candesartan dose, without an increase in adverse events. Azilsartan may provide renal protection in addition to antihypertensive effects in CKD patients.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Benzimidazoles/therapeutic use , Biphenyl Compounds/therapeutic use , Oxadiazoles/therapeutic use , Proteinuria/drug therapy , Renal Insufficiency, Chronic/drug therapy , Tetrazoles/therapeutic use , Angiotensin II Type 1 Receptor Blockers/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Benzimidazoles/pharmacology , Biphenyl Compounds/pharmacology , Cross-Over Studies , Female , Humans , Male , Middle Aged , Oxadiazoles/pharmacology , Tetrazoles/pharmacology
3.
BMC Nephrol ; 18(1): 288, 2017 Sep 06.
Article in English | MEDLINE | ID: mdl-28877681

ABSTRACT

BACKGROUND: Fibronectin glomerulopathy is a rare, inherited, autosomal dominant, glomerular disease characterized by proteinuria, microscopic hematuria, hypertension, massive glomerular deposits of fibronectin, and slow progression to end-stage renal failure. Because the incident of fibronectin glomerulopathy is extremely low, the pathophysiology, genetic abnormalities, epidemiology, and mechanisms remain to be elucidated. CASE PRESENTATION: We report a 21-year-old woman with fibronectin glomerulopathy, who had been diagnosed with persistent cloaca and congenital esophageal atresia at birth. She developed proteinuria and hematuria 7 months before admission. Urinary protein and serum creatinine levels were 3.38 g/gCr and 0.73 mg/dL. Renal biopsy showed severe mesangial widening due to massive deposits, which was positive periodic acid-Schiff and negative methenamine silver. Immunostaining was negative for immunoglobulin but positive for fibronectin. Electron microscopy showed diffuse mesangial granular deposits. Thus she was diagnosed with fibronectin glomerulopathy, despite a negative family history of kidney disease and lack of any known missense mutations of fibronectin 1 gene. CONCLUSION: We report a patient who developed fibronectin glomerulopathy during the clinical course of extremely rare congenital malformations, including persistent cloaca and congenital esophageal atresia. We describe a case of this condition in detail and summarize the 75 case reports of fibronectin glomerulopathy.


Subject(s)
Cloaca/pathology , Esophageal Atresia/diagnosis , Esophageal Atresia/genetics , Glomerulonephritis, Membranoproliferative/diagnosis , Glomerulonephritis, Membranoproliferative/genetics , Esophageal Atresia/complications , Female , Glomerulonephritis, Membranoproliferative/complications , Humans , Young Adult
4.
Ren Fail ; 38(3): 390-6, 2016.
Article in English | MEDLINE | ID: mdl-26822074

ABSTRACT

BACKGROUND: Controversy exists regarding the renoprotective effect of erythropoiesis-stimulating agent (ESA) in progressive chronic kidney disease (CKD) with renal anemia. In this study, we examined whether ESA therapy has a renoprotective effect in progressive CKD. METHODS: The subjects in this retrospective observational study were 68 non-dialysis dependent CKD patients with renal anemia. We compared the progression rate (PR), defined by the slope of the linear regression line of estimated glomerular filtration rate, measured during 6 months just before and after the start of ESA therapy. We also investigated the factors affecting renoprotective efficacy of ESA therapy against the progression of CKD. RESULTS: Median (interquartile range) PR decreased significantly from 6.2 (3.7-12.7) to 4.0 (-0.3 to 7.3) mL/min/1.73 m(2)/year after the start of ESA therapy. Blood pressure levels and rate of medication with renin-angiotensin system inhibitors were comparable between the two periods. Next, we investigated the factors affecting renoprotective efficacy of ESA therapy against the progression of CKD. Thirty patients were good renal responders, defined as those with the ratio of post-/pre-PR of <0.5 and the difference of pre- minus post-PR >5.0 mL/min/1.73 m(2)/year, and 38 patients were poor renal responders who did not meet the definition of good renal responders. Multivariable logistic regression analysis showed that weekly ESA dose, but not increase in hemoglobin level, was a significant and independent determinant of the renoprotective effect of ESA. CONCLUSION: ESA therapy slows the progression of CKD and part of the effect might be attributed to the direct renoprotective action of ESA.


Subject(s)
Anemia/drug therapy , Epoetin Alfa/administration & dosage , Erythropoiesis/drug effects , Hematinics/administration & dosage , Renal Insufficiency, Chronic/complications , Renin-Angiotensin System/drug effects , Aged , Blood Pressure/drug effects , Disease Progression , Female , Hemoglobins/drug effects , Humans , Japan , Kidney/drug effects , Logistic Models , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Treatment Outcome
5.
Ther Apher Dial ; 20(1): 31-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26482334

ABSTRACT

Selection of a lower dialysate calcium concentration (DCa) can reduce calcium burden and prevent vascular calcification in hemodialysis patients. However, decreased DCa can worsen mineral and bone disorders. This 1-year retrospective observational study evaluated 121 hemodialysis patients at Fukuoka Renal Clinic who underwent conversion of DCa from 3.0 mEq/L to 2.75 mEq/L. The primary outcomes were changes in serum levels of calcium, phosphate, and parathyroid hormone (PTH). The effects of baseline serum calcium and PTH levels on changes in biochemical parameters were also determined. One year after DCa conversion, mean serum calcium level decreased, while serum phosphate, alkaline phosphatase, and PTH concentrations increased. The rate of achievement of target PTH was higher in patients with lower serum PTH level at baseline, while patients with higher baseline serum PTH level tended to exceed the upper limit of the PTH target range. Patients with higher baseline serum calcium concentration showed a greater decrease in serum calcium level and a greater increase in serum PTH level at 1 year. Patients with a lower baseline serum PTH level can benefit from optimal PTH control following conversion of DCa from 3.0 mEq/L to 2.75 mEq/L. However, secondary hyperparathyroidism may be exacerbated in some patients with higher baseline serum calcium (Ca) and PTH levels. These results indicate that an individualized approach can maximize the benefits of Ca unloading after conversion to lower DCa.


Subject(s)
Bone Diseases , Calcium , Hemodialysis Solutions , Hyperparathyroidism, Secondary , Kidney Failure, Chronic , Renal Dialysis , Vascular Calcification , Aged , Alkaline Phosphatase , Bone Diseases/diagnosis , Bone Diseases/etiology , Bone Diseases/prevention & control , Calcium/analysis , Calcium/blood , Female , Hemodialysis Solutions/chemistry , Hemodialysis Solutions/pharmacology , Humans , Hyperparathyroidism, Secondary/diagnosis , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/prevention & control , Japan , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Outcome and Process Assessment, Health Care , Parathyroid Hormone/blood , Phosphates/blood , Renal Dialysis/adverse effects , Renal Dialysis/methods , Statistics as Topic , Vascular Calcification/diagnosis , Vascular Calcification/etiology , Vascular Calcification/prevention & control
6.
Case Rep Nephrol Dial ; 5(3): 187-91, 2015.
Article in English | MEDLINE | ID: mdl-26558252

ABSTRACT

Ceftriaxone (CTRX) is a third-generation cephalosporin widely used for the treatment of bacterial infections in patients with renal disease because of its excretion by both renal and hepatic mechanisms. Biliary pseudolithiasis is a known CTRX-associated complication; however, there have been no studies of this adverse event in adult patients receiving maintenance hemodialysis. Here we report the case of a 79-year-old Japanese woman with end-stage renal disease (ESRD) receiving maintenance hemodialysis who developed CTRX-induced pseudolithiasis. The patient received CTRX for bronchial pneumonia. Fifteen days following CTRX initiation, the patient presented with stomachache. Because of the presence of one gallstone and increased gallbladder wall thickness on computed tomography scans, not detected at the onset of pneumonia, the patient was diagnosed with CTRX-induced gallbladder pseudolithiasis. CTRX was discontinued immediately. At 48 days following CTRX withdrawal, the gallstone and thickening of the gallbladder wall had completely resolved. ESRD may be a risk factor for CTRX-induced pseudolithiasis as hepatic excretion of CTRX is the predominant clearance mechanism in patients with ESRD. More attention should be paid to CTRX-induced pseudolithiasis following the use of CTRX in ESRD patients.

7.
Ther Apher Dial ; 19(4): 367-77, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25851690

ABSTRACT

The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT). The present study was a prospective observational study to determine the effect of cinacalcet treatment on PTG volume and serum biochemical parameters in 60 patients with renal SHPT, already treated with intravenous vitamin D receptor activator (VDRA). Measurement of biochemical parameters and PTG volumes were performed periodically, which were analyzed by stratification into tertiles across the baseline parathyroid hormone (PTH) level or PTG volume. We also determined the factors that can estimate the changes in PTG volume and the achievement of the target PTH range by multivariable analyses. Two years of cinacalcet treatment significantly decreased the serum levels of PTH, calcium, and phosphate, followed by the improvement of achieving the target ranges for these parameters recommended by the Japanese Society for Dialysis Therapy. Cinacalcet decreased the maximal and total PTG volume by about 30%, and also decreased the serum PTH level independent of the baseline serum PTH level and PTG volume. Ten out of 60 patients showed 30% increase in maximal PTG after 2 years. Multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at two years. In conclusion, cinacalcet treatment with intravenous VDRA therapy decreased both PTG volume and serum intact PTH level, irrespective of the pretreatment PTG status and past treatment history.


Subject(s)
Calcimimetic Agents , Hyperparathyroidism, Secondary , Kidney Failure, Chronic , Parathyroid Glands , Parathyroid Hormone/blood , Renal Dialysis , Aged , Calcimimetic Agents/administration & dosage , Calcimimetic Agents/adverse effects , Cinacalcet/administration & dosage , Cinacalcet/adverse effects , Female , Humans , Hyperparathyroidism, Secondary/blood , Hyperparathyroidism, Secondary/complications , Hyperparathyroidism, Secondary/diagnosis , Hyperparathyroidism, Secondary/therapy , Japan , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Organ Size , Parathyroid Glands/drug effects , Parathyroid Glands/pathology , Prognosis , Prospective Studies , Renal Dialysis/adverse effects , Renal Dialysis/methods , Risk Assessment/methods , Severity of Illness Index , Time
8.
Endocrinology ; 156(7): 2657-66, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25872005

ABSTRACT

Chronic inhibition of nitric oxide synthase by N(ω)-nitro-L-arginine methyl ester (L-NAME) causes progressive renal injury and systemic hypertension. Angiotensin II (Ang II) has been conventionally regarded as one of the primary causes of renal injury. We reported previously that such renal injury was almost completely suppressed by both an Ang II type I receptor blocker and an aldosterone antagonist. The aldosterone antagonist also inhibited the systemic Ang II elevation. Therefore, it remains to be elucidated whether Ang II or aldosterone directly affects the development of such renal injury. In the present study, we investigated the role of aldosterone in the pathogenesis of renal injury induced by L-NAME-mediated chronic nitric oxide synthase inhibition in male Wistar rats (aged 10 wk). Serial analyses demonstrated that the renal injury and inflammation in L-NAME-treated rats was associated with elevation of both Ang II and aldosterone. To investigate the direct effect of aldosterone on the renal injury, we conducted adrenalectomy (ADX) and aldosterone supplementation in L-NAME-treated rats. In ADX rats, aldosterone was undetectable, and renal injury and inflammation were almost completely prevented by ADX, although systemic and local Ang II and blood pressure were still elevated. Aldosterone supplementation reversed the beneficial effect of ADX. The present study indicates that aldosterone rather than Ang II plays a central and direct role in the pathogenesis of renal injury by L-NAME through inflammation, independent of its systemic hemodynamic effects.


Subject(s)
Adrenalectomy , Aldosterone/metabolism , Angiotensin II/drug effects , Enzyme Inhibitors/pharmacology , Kidney/drug effects , NG-Nitroarginine Methyl Ester/pharmacology , RNA, Messenger/drug effects , Renal Insufficiency, Chronic/metabolism , Aldosterone/pharmacology , Angiotensin II/metabolism , Animals , Blood Pressure/drug effects , Chemokine CCL2/drug effects , Chemokine CCL2/genetics , Disease Models, Animal , Kidney/metabolism , Kidney/pathology , Macrophages/drug effects , Male , Nitric Oxide/deficiency , Nitric Oxide Synthase/antagonists & inhibitors , Osteopontin/drug effects , Osteopontin/genetics , RNA, Messenger/metabolism , Rats , Renal Insufficiency, Chronic/pathology , Renin-Angiotensin System/drug effects , Time Factors , Transforming Growth Factor beta1/drug effects , Transforming Growth Factor beta1/genetics
9.
CEN Case Rep ; 4(1): 14-19, 2015 May.
Article in English | MEDLINE | ID: mdl-28509269

ABSTRACT

A 61-year-old woman was admitted to our hospital because of an unexpected rise in serum creatinine (sCr) level with proteinuria and microhematuria. She had undergone living-donor kidney transplantation 31 years before for end-stage renal disease caused by chronic glomerulonephritis (GN). On admission, her sCr was 1.27 mg/dL which was increased from 0.6 mg/dL, urinary protein/creatinine ratio was 1.39 g/gCr, and urinary red blood cell count was more than 100 per high power field. The allograft biopsy revealed crescentic glomerulonephritis with moderate to severe tubulointerstitial inflammation. Immunofluorescence staining yielded only a minimal staining for immunoglobulin A, and negative C4d in peritubular capillary. Since increased myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titer of 45.5 U/mL was detected, we made the diagnosis of post-transplant MPO-ANCA-associated GN. She was treated with three doses of bolus methylprednisolone (500 mg) followed by oral prednisolone therapy. Her sCr was stable at 1.20 mg/dL thereafter. ANCA-associated GN should be considered in older kidney transplant patients with new-onset urinary abnormalities because typical systemic symptoms and vasculitis in other organs might be masked by maintenance immunosuppression.

10.
Kidney Int ; 87(1): 116-27, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24940798

ABSTRACT

We elucidate the underlying mechanisms of bidirectional cardiorenal interaction, focusing on the sympathetic nerve driving disruption of the local renin-angiotensin system (RAS). A rat model of N(ω)-nitro-L-arginine methyl ester (L-NAME; a nitric oxide synthase inhibitor) administration was used to induce damage in the heart and kidney, similar to cardiorenal syndrome. L-NAME induced sympathetic nerve-RAS overactivity and cardiorenal injury accompanied by local RAS elevations. These were suppressed by bilateral renal denervation, but not by hydralazine treatment, despite the blood pressure being kept the same between the two groups. Although L-NAME induced angiotensinogen (AGT) protein augmentation in both organs, AGT mRNA decreased in the kidney and increased in the heart in a contradictory manner. Immunostaining for AGT suggested that renal denervation suppressed AGT onsite generation from activated resident macrophages of the heart and circulating AGT excretion from glomeruli of the kidney. We also examined rats treated with L-NAME plus unilateral denervation to confirm direct sympathetic regulation of intrarenal RAS. The levels of urinary AGT and renal angiotensin II content and the degrees of renal injury from denervated kidneys were less than those from contralateral innervated kidneys within the same rats. Thus, renal denervation has blood pressure-independent beneficial effects associated with local RAS inhibition.


Subject(s)
Cardio-Renal Syndrome/prevention & control , Heart Diseases/prevention & control , Kidney/innervation , Sympathectomy , Animals , Blood Pressure , Cardio-Renal Syndrome/etiology , Disease Models, Animal , Heart Diseases/etiology , Male , Rats , Rats, Wistar , Renal Insufficiency, Chronic/complications , Renin-Angiotensin System/physiology , Sympathetic Nervous System/physiology
11.
J Bone Miner Res ; 27(2): 474-85, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21987400

ABSTRACT

Vascular calcification is closely related to cardiovascular morbidity and mortality. Accumulating data indicate that oxidative stress is associated with dysfunction of various organs, including cardiovascular diseases in chronic kidney disease (CKD). However, it remains undetermined if oxidative stress induced by uremia promotes arterial medial calcification. The present study investigated the role of oxidative stress in the pathogenesis of arterial medial calcification in uremic rats. Rats with uremia induced by adenine-rich diet progressively developed arterial medial calcification, which was accompanied by time-dependent increases in both aortic and systemic oxidative stress. Immunohistochemical and biochemical analyses showed that the arterial medial calcification progressed in a time-dependent manner that is parallel to the osteogenic transdifferentiation of vascular smooth muscle cells. Accumulation of oxidative stress was also identified in the calcified regions. Time-course studies indicated that both oxidative stress and hyperphosphatemia correlated with arterial medial calcification. Tempol, an antioxidant, ameliorated osteogenic transdifferentiation of vascular smooth muscle cells and arterial medial calcification in uremic rats, together with reduction in aortic and systemic oxidative stress levels, without affecting serum biochemical parameters. Our data suggest that oxidative stress induced by uremia can play a role in the pathogenesis of vascular calcification in CKD, and that antioxidants such as tempol are potentially useful in preventing the progression of vascular calcification in CKD.


Subject(s)
Antioxidants/pharmacology , Calcinosis/prevention & control , Cyclic N-Oxides/pharmacology , Kidney Failure, Chronic/complications , Oxidative Stress/drug effects , Tunica Media/pathology , Uremia/complications , Animals , Aorta, Abdominal/drug effects , Aorta, Abdominal/enzymology , Aorta, Abdominal/pathology , Arteries/drug effects , Arteries/pathology , Biomarkers/metabolism , Calcinosis/blood , Calcinosis/etiology , Calcinosis/pathology , Cell Transdifferentiation/drug effects , Hyperphosphatemia/blood , Hyperphosphatemia/complications , Hyperphosphatemia/pathology , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/pathology , Male , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , NADPH Oxidases/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/pathology , Osteogenesis/drug effects , Phenotype , Rats , Rats, Sprague-Dawley , Spin Labels , Tunica Media/drug effects , Uremia/blood , Uremia/pathology
12.
Clin Exp Nephrol ; 13(5): 518-521, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19459028

ABSTRACT

A 40-year-old man was transferred to our hospital because of severe anasarca. He was a heavy drinker for more than 20 years, and diagnosed with diabetes mellitus 8 years earlier and treated with retinal photocoagulation 8 months earlier. He reported loss of appetite after divorce 10 months prior to admission. On admission, he presented with systemic edema and dyspnea. Chest radiography showed massive pleural effusion and cardiomegaly. Serum total protein was 5.6 g/dl, albumin 2.6 g/dl, and urinary protein excretion was 5.3 g/day. Glucose tolerance test showed normal pattern. Ultrafiltration and continuous hemofiltration resulted in loss of 40 kg body weight in 5 days. Echocardiography revealed high-output heart failure and blood tests showed low serum thiamine level of 12 ng/ml (normal, >28 ng/ml). Accordingly, the diagnosis was established as beriberi heart disease complicated with nephrotic syndrome. Treatment with 50 mg/day thiamine intravenously and 80 mg/day furosemide resulted in increase in urine output, decrease in cardiac output, resolution of pulmonary effusion, and about 70 kg body weight loss. Percutaneous renal biopsy showed nodular glomerulosclerosis, mesangial matrix expansion, and thickening of glomerular basement membrane (GBM). Immunofluorescence study showed no glomerular deposition of immunoglobulin or complement. Electron microscopy showed GBM thickening and mesangial matrix deposition without electron-dense deposits or fibrils. These findings were compatible with diabetic glomerulosclerosis. In this patient, extreme malnutrition altered glucose tolerance but, on the other hand, nephrotic syndrome associated with diabetic nephropathy made the diagnosis of beriberi heart disease difficult.


Subject(s)
Beriberi/complications , Diabetic Nephropathies/complications , Edema/etiology , Heart Diseases , Adult , Beriberi/pathology , Diabetes Mellitus/pathology , Diabetic Nephropathies/pathology , Heart Diseases/complications , Heart Diseases/etiology , Humans , Kidney Glomerulus/pathology , Male
13.
Ren Fail ; 30(8): 813-7, 2008.
Article in English | MEDLINE | ID: mdl-18791957

ABSTRACT

IgA nephropathy associated with liver cirrhosis is a common disease, unlike hemochromatosis-associated renal involvement, which is uncommon. A 55-year-old man was admitted to our hospital for the acute deterioration of renal function. Laboratory tests showed extremely high transferrin saturation and serum ferritin level. Furthermore, magnetic resonance imaging revealed low-intensity signals in both T1- and T2-weighted images within the liver, diagnosed as primary hemochromatosis. Renal biopsy showed mesangial IgA deposition with cellular crescent and hemosiderin in both glomerular and tubular epithelial cells. Renal function worsened progressively after admission, and thus steroid pulse therapy was started. Renal dysfunction improved, but the patient died of cerebral hemorrhage. The present case was considered IgA nephropathy and renal hemosiderosis secondary to primary hemochromatosis. To our knowledge, this is the first report that describes the above complications in association with primary hemochromatosis.


Subject(s)
Glomerulonephritis, IGA/etiology , Hemochromatosis/complications , Hemosiderosis/etiology , Humans , Male , Middle Aged
14.
Intern Med ; 46(5): 241-5, 2007.
Article in English | MEDLINE | ID: mdl-17329920

ABSTRACT

A 60-year-old woman was admitted because of multiple bone pain. Examination revealed hypophosphatemic osteomalacia and acquired Fanconi syndrome. Further exploration revealed monoclonal gammopathy of undetermined significance (MGUS) excreting urinary Bence Jones protein (kappa light chain). Renal biopsy showed non-specific tubulointerstitial nephritis, yet neither crystalline inclusions in the cytoplasm of the tubular epithelium nor myeloma casts nor amyloid deposits were found. She was treated with supplementation by phosphate, alkali agents, and vitamin D, and responded well to the treatment symptomatically and biochemically. MGUS was observed without chemotherapy. Myeloma had not developed after 10 months follow-up.


Subject(s)
Fanconi Syndrome/etiology , Osteomalacia/etiology , Paraproteinemias/complications , Alkalies/therapeutic use , Bence Jones Protein/urine , Drug Therapy, Combination , Fanconi Syndrome/drug therapy , Female , Humans , Immunoglobulin kappa-Chains/urine , Kidney/pathology , Middle Aged , Nephritis, Interstitial/etiology , Nephritis, Interstitial/pathology , Osteomalacia/diagnostic imaging , Osteomalacia/drug therapy , Paraproteinemias/urine , Phosphates/therapeutic use , Radiography , Radionuclide Imaging , Tibial Fractures/diagnostic imaging , Tibial Fractures/etiology , Vitamin D/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...